4c59 Citations

Structure of cyclin G-associated kinase (GAK) trapped in different conformations using nanobodies.

Abstract

GAK (cyclin G-associated kinase) is a key regulator of clathrin-coated vesicle trafficking and plays a central role during development. Additionally, due to the unusually high plasticity of its catalytic domain, it is a frequent 'off-target' of clinical kinase inhibitors associated with respiratory side effects of these drugs. In the present paper, we determined the crystal structure of the GAK catalytic domain alone and in complex with specific single-chain antibodies (nanobodies). GAK is constitutively active and weakly associates in solution. The GAK apo structure revealed a dimeric inactive state of the catalytic domain mediated by an unusual activation segment interaction. Co-crystallization with the nanobody NbGAK_4 trapped GAK in a dimeric arrangement similar to the one observed in the apo structure, whereas NbGAK_1 captured the activation segment of monomeric GAK in a well-ordered conformation, representing features of the active kinase. The presented structural and biochemical data provide insight into the domain plasticity of GAK and demonstrate the utility of nanobodies to gain insight into conformational changes of dynamic molecules. In addition, we present structural data on the binding mode of ATP mimetic inhibitors and enzyme kinetic data, which will support rational inhibitor design of inhibitors to reduce the off-target effect on GAK.

Reviews - 4c59 mentioned but not cited (1)

  1. COVID-19: Drug Targets and Potential Treatments. Gil C, Ginex T, Maestro I, Nozal V, Barrado-Gil L, Cuesta-Geijo MÁ, Urquiza J, Ramírez D, Alonso C, Campillo NE, Martinez A. J Med Chem 63 12359-12386 (2020)

Articles - 4c59 mentioned but not cited (3)



Reviews citing this publication (14)

  1. Nanobodies and recombinant binders in cell biology. Helma J, Cardoso MC, Muyldermans S, Leonhardt H. J Cell Biol 209 633-644 (2015)
  2. Camelid nanobodies: killing two birds with one stone. Desmyter A, Spinelli S, Roussel A, Cambillau C. Curr Opin Struct Biol 32 1-8 (2015)
  3. Nanobodies as Probes for Protein Dynamics in Vitro and in Cells. Dmitriev OY, Lutsenko S, Muyldermans S. J Biol Chem 291 3767-3775 (2016)
  4. Antigen recognition by single-domain antibodies: structural latitudes and constraints. Henry KA, MacKenzie CR. MAbs 10 815-826 (2018)
  5. Distinct antibody species: structural differences creating therapeutic opportunities. Muyldermans S, Smider VV. Curr Opin Immunol 40 7-13 (2016)
  6. Oral antiviral treatments for COVID-19: opportunities and challenges. Rahmah L, Abarikwu SO, Arero AG, Essouma M, Jibril AT, Fal A, Flisiak R, Makuku R, Marquez L, Mohamed K, Ndow L, Zarębska-Michaluk D, Rezaei N, Rzymski P. Pharmacol Rep 74 1255-1278 (2022)
  7. DNAJC proteins and pathways to parkinsonism. Roosen DA, Blauwendraat C, Cookson MR, Lewis PA. FEBS J 286 3080-3094 (2019)
  8. Allosteric inhibition of LRRK2, where are we now. Soliman A, Cankara FN, Kortholt A. Biochem Soc Trans 48 2185-2194 (2020)
  9. The Intersection of Structural and Chemical Biology - An Essential Synergy. Zuercher WJ, Elkins JM, Knapp S. Cell Chem Biol 23 173-182 (2016)
  10. Micro RNAs-The Small Big Players in Hepatitis E Virus Infection: A Comprehensive Review. Golkocheva-Markova E. Biomolecules 12 1543 (2022)
  11. Structural Insight into TNIK Inhibition. Kukimoto-Niino M, Shirouzu M, Yamada T. Int J Mol Sci 23 13010 (2022)
  12. Nanobodies in the fight against infectious diseases: repurposing nature's tiny weapons. Rizk SS, Moustafa DM, ElBanna SA, Nour El-Din HT, Attia AS. World J Microbiol Biotechnol 40 209 (2024)
  13. Recent progress in discovery of novel AAK1 inhibitors: from pain therapy to potential anti-viral agents. Yuan YH, Mao ND, Duan JL, Zhang H, Garrido C, Lirussi F, Gao Y, Xie T, Ye XY. J Enzyme Inhib Med Chem 38 2279906 (2023)
  14. From discovery to treatment: tracing the path of hepatitis E virus. Letafati A, Taghiabadi Z, Roushanzamir M, Memarpour B, Seyedi S, Farahani AV, Norouzi M, Karamian S, Zebardast A, Mehrabinia M, Ardekani OS, Fallah T, Khazry F, Daneshvar SF, Norouzi M. Virol J 21 194 (2024)

Articles citing this publication (17)